Increased incidence of aflatoxin B1-induced liver tumors in hepatitis virus C transgenic mice

International Journal of Cancer

Volumn 130, Issue 6, 2012, Pages 1347-1356

  Jeannot, Emmanuelle ^a   Boorman, Gary A ^b   Kosyk, Oksana ^a   Bradford, Blair U ^a   Shymoniak, Svitlana ^a   Tumurbaatar, Batbayar ^c   Weinman, Steven A ^c   Melnyk, Stepan B ^d   Tryndyak, Volodymyr ^e   Pogribny, Igor P ^e   Rusyn, Ivan ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UK   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

aflatoxin B1; hepatitis C virus; liver; mouse

Indexed keywords

AFLATOXIN B1; TRIOCTANOIN; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CARCINOGEN TESTING; CONTROLLED STUDY; FATTY LIVER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPATITIS C VIRUS; LIPID METABOLISM; LIPID PEROXIDATION; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CARCINOMA; LIVER CELL CARCINOMA; LIVER HISTOLOGY; LIVER HYPERPLASIA; LONG TERM EXPOSURE; MALE; MOLECULAR DYNAMICS; MOUSE; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROGENY; PROTEIN INTERACTION; PROTEIN UNFOLDING; TRANSGENIC MOUSE; VIRAL GENETICS; VIRUS CORE; VIRUS EXPRESSION;

AFLATOXIN B1; ANIMALS; FATTY LIVER; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; INFLAMMATION; LIPID METABOLISM; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OXIDATIVE STRESS;

EID: 84856111592     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26140     Document Type: Article

References (44)

1. El Serag HB, Rudolph KL,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76. (Pubitemid 46890874)
2. Bosch FX, Ribes J, Diaz M, Cleries R,. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16. (Pubitemid 39423365)
3. Jepsen P, Vilstrup H, Tarone RE, Friis S, Sorensen HT,. Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. Int J Cancer 2007; 121: 1624-6. (Pubitemid 47328724)
4. International Agency for Research on Cancer. World cancer report 2008. Lyon, France: IARC Press, 2008.
5. London WT, Evans AA, McGlynn K, Buetow K, An P, Gao L, Lustbader E, Ross E, Chen G, Shen F,. Viral, host and environmental risk factors for hepatocellular carcinoma: a prospective study in Haimen City, China. Intervirology 1995; 38: 155-61. (Pubitemid 26009386)
6. International Agency for Research on Cancer. Some naturally occurring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins. Lyon, France: IARC Press, 1993.
7. Garner RC, Miller EC, Miller JA,. Liver microsomal metabolism of aflatoxin B1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Res 1972; 32: 2058-66.
8. Foster PL, Eisenstadt E, Miller JH,. Base substitution mutations induced by metabolically activated aflatoxin B1. Proc Natl Acad Sci USA 1983; 80: 2695-8. (Pubitemid 13093375)
9. Chen CH, Wang MH, Wang JH, Hung CH, Hu TH, Lee SC, Tung HD, Lee CM, Changchien CS, Chen PF, Hsu MC, Lu SN,. Aflatoxin exposure and hepatitis C virus in advanced liver disease in a hepatitis C virus endemic area in Taiwan. Am J Trop Med Hyg 2007; 77: 747-52.
10. Sayed HA, El Ayyat A, El Dusoki H, Zoheiry M, Mohamed S, Hassan M, El Assaly N, Awad A, El Ansary M, Saad A, El Karim AA,. A cross sectional study of hepatitis B, C, some trace elements, heavy metals, aflatoxin B1 and schistosomiasis in a rural population, Egypt. J Egypt Public Health Assoc 2005; 80: 355-88.
11. Vesselinovitch SD, Mihailovich N, Wogan GN, Lombard LS, Rao KV,. Aflatoxin B 1, a hepatocarcinogen in the infant mouse. Cancer Res 1972; 32: 2289-91.
12. McGlynn KA, Hunter K, LeVoyer T, Roush J, Wise P, Michielli RA, Shen FM, Evans AA, London WT, Buetow KH,. Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res 2003; 63: 4594-601. (Pubitemid 36951035)
13. Liu SP, Li YS, Lee CM, Yen CH, Liao YJ, Huang SF, Chien CH, Chen YM,. Higher susceptibility to aflatoxin B(1)-related hepatocellular carcinoma in glycine N-methyltransferase knockout mice. Int J Cancer 2011; 128: 511-23.
14. Bradley DW,. Studies of non-A, non-B hepatitis and characterization of the hepatitis C virus in chimpanzees. Curr Top Microbiol Immunol 2000; 242: 1-23. (Pubitemid 29467518)
15. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K,. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-7. (Pubitemid 28417341)
16. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman SA, Lemon SM,. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002; 122: 352-65. (Pubitemid 34116987)
17. Koike K, Moriya K, Matsuura Y,. Animal models for hepatitis C and related liver disease. Hepatol Res 2010; 40: 69-82.
18. Liang TJ, Heller T,. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004; 127: S62-S71. (Pubitemid 39423371)
19. Naas T, Ghorbani M, Alvarez-Maya I, Lapner M, Kothary R, De Repentigny Y, Gomes S, Babiuk L, Giulivi A, Soare C, Azizi A, Diaz-Mitoma F,. Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol 2005; 86: 2185-96. (Pubitemid 41057523)
20. Machida K, Tsukamoto H, Mkrtchyan H, Duan L, Dynnyk A, Liu HM, Asahina K, Govindarajan S, Ray R, Ou JH, Seki E, Deshaies R, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci USA 2009; 106: 1548-53.
21. Fox JG, Feng Y, Theve EJ, Raczynski AR, Fiala JL, Doernte AL, Williams M, McFaline JL, Essigmann JM, Schauer DB, Tannenbaum SR, Dedon PC, et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 2010; 59: 88-97.
22. Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J, Weinman SA,. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 2005; 280: 37481-8. (Pubitemid 41642356)
23. James SJ, Rose S, Melnyk S, Jernigan S, Blossom S, Pavliv O, Gaylor DW,. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J 2009; 23: 2374-83.
24. Milano J, Day BJ,. A catalytic antioxidant metalloporphyrin blocks hydrogen peroxide-induced mitochondrial DNA damage. Nucleic Acids Res 2000; 28: 968-73. (Pubitemid 30085324)
25. Demeilliers C, Maisonneuve C, Grodet A, Mansouri A, Nguyen R, Tinel M, Letteron P, Degott C, Feldmann G, Pessayre D, Fromenty B,. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology 2002; 123: 1278-90.
26. Powell CL, Kosyk O, Ross PK, Schoonhoven R, Boysen G, Swenberg JA, Heinloth AN, Boorman GA, Cunningham ML, Paules RS, Rusyn I,. Phenotypic anchoring of acetaminophen-induced oxidative stress with gene expression profiles in rat liver. Toxicol Sci 2006; 93: 213-22. (Pubitemid 44288265)
27. Piver E, Roingeard P, Pages JC,. The cell biology of hepatitis C virus (HCV) lipid addiction: molecular mechanisms and its potential importance in the clinic. Int J Biochem Cell Biol 2010; 42: 869-79.
28. Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T,. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 2008; 118: 683-94. (Pubitemid 351206557)
29. Negro F, Sanyal AJ,. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009; 29 (Suppl 2): 26-37.
30. Colon AR,. Hepatic steatosis in children. Am J Gastroenterol 1977; 68: 260-9. (Pubitemid 8295309)
31. Sachan DS, Yatim AM,. Suppression of aflatoxin B1-induced lipid abnormalities and macromolecule-adduct formation by L-carnitine. J Environ Pathol Toxicol Oncol 1992; 11: 205-10.
32. Ankrah NA, Addo PG, Abrahams CA, Ekuban FA, Addae MM,. Comparative effects of aflatoxins G1 and B1 at levels within human exposure limits on mouse liver and kidney. West Afr J Med 1993; 12: 105-9.
33. Chan SW, Egan PA,. Hepatitis C virus envelope proteins regulate CHOP via induction of the unfolded protein response. FASEB J 2005; 19: 1510-12. (Pubitemid 41279014)
34. Lerat H, Kammoun HL, Hainault I, Merour E, Higgs MR, Callens C, Lemon SM, Foufelle F, Pawlotsky JM,. Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. J Biol Chem 2009; 284: 33466-74.
35. Nishina S, Korenaga M, Hidaka I, Shinozaki A, Sakai A, Gondo T, Tabuchi M, Kishi F, Hino K,. Hepatitis C virus protein and iron overload induce hepatic steatosis through the unfolded protein response in mice. Liver Int 2010; 30: 683-92.
36. Rutkowski DT, Wu J, Back SH, Callaghan MU, Ferris SP, Iqbal J, Clark R, Miao H, Hassler JR, Fornek J, Katze MG, Hussain MM, et al. UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. Dev Cell 2008; 15: 829-40.
37. Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L, Wang J, Wu Y, Liu G, Wu Y, Zhu Y,. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 1999; 30: 379-83. (Pubitemid 29357500)
38. Yu MW, Lien JP, Chiu YH, Santella RM, Liaw YF, Chen CJ,. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J Hepatol 1997; 27: 320-30. (Pubitemid 27366213)
39. Anwar WA, Khaled HM, Amra HA, El Nezami H, Loffredo CA,. Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat Res 2008; 659: 176-84.
40. Eaton DL, Gallagher EP,. Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol 1994; 34: 135-72.
41. Ilic Z, Crawford D, Vakharia D, Egner PA, Sell S,. Glutathione-S- transferase A3 knockout mice are sensitive to acute cytotoxic and genotoxic effects of aflatoxin B1. Toxicol Appl Pharmacol 2010; 242: 241-6.
42. Kensler TW, Roebuck BD, Wogan GN, Groopman JD,. Aflatoxin: a 50 year odyssey of mechanistic and translational toxicology. Toxicol Sci 2011; 120 Suppl 1: S28-48.
43. Furutani T, Hino K, Okuda M, Gondo T, Nishina S, Kitase A, Korenaga M, Xiao SY, Weinman SA, Lemon SM, Sakaida I, Okita K,. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006; 130: 2087-98. (Pubitemid 43816966)
44. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001; 61: 4365-70. (Pubitemid 32685760)